XML 86 R76.htm IDEA: XBRL DOCUMENT
v3.25.2

FAIR VALUE - Narrative (Details) |  |  |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 17, 2025 USD ($) | Sep. 16, 2024 USD ($) | Feb. 22, 2024 USD ($) | Dec. 12, 2023 USD ($) | May 17, 2021 USD ($) | Dec. 31, 2024 USD ($) | Jun. 30, 2025 USD ($) shares | Jun. 30, 2024 USD ($) | Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($) guarantee
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Money Market Fund |  |  |  |  |  | $ 84,277,000 | $ 136,280,000 |  |  | $ 84,277,000
Interest rate swap |  |  |  |  |  | 4,897,000 | $ 2,812,000 |  |  | 4,897,000
Achievement of milestones payment period |  |  |  |  |  |  | 24 months |  |  |
Payments on contingent consideration |  |  |  |  |  |  | $ 0 | $ 12,500,000 |  |
Contingent consideration, Novitium |  |  |  |  |  | 10,900,000 | 12,600,000 |  |  | 10,900,000
Payments for royalties | $ 17,300,000 |  |  |  |  |  |  |  |  |
Novitium |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Additional contingent consideration |  |  |  |  |  |  | 46,500,000 |  |  |
Payments on contingent consideration |  |  | $ 12,500,000 | $ 12,500,000 |  |  |  |  |  |
Contingent consideration, Novitium |  |  |  |  |  | 10,854,000 | 12,572,000 |  |  | 10,854,000
Alimera Sciences, Inc |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, Novitium |  |  |  |  |  | 9,000,000 | 6,000,000 |  |  | $ 9,000,000
Novitium |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Fair value of payments |  |  |  |  |  |  | $ 21,500,000 |  |  |
Net profit generated by the sales |  |  |  |  |  |  | 20.00% |  |  |
Collaborative arrangement, percentage of net profit generated by sales, quarterly payment due, accrued |  |  |  |  |  |  | $ 45,000 |  |  |
CG Oncology |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Shares held (in shares) | shares |  |  |  |  |  |  | 219,925 |  |  |
Closing price |  |  |  |  |  |  | $ 26.00 |  |  |
Accrued Licensor Payments |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Fair value of payments |  |  |  |  |  |  | 5,700,000 |  |  |
Up-front payment |  |  |  |  | $ 75,000,000 |  |  |  |  |
Number of quarterly guaranteed payment | guarantee |  |  |  |  |  |  |  |  |  | 4
Additional milestone payment |  |  |  |  |  |  |  |  |  | $ 7,500,000
Accrued Licensor Payments | Forecast |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Collaborative arrangement royalty payable on net revenue revenue threshold |  |  |  |  |  |  |  |  | $ 70,000,000 |
Eye Point Agreements Member |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Fair value of payments |  |  |  |  |  |  | 11,400,000 |  |  |
Payments for royalties |  |  |  |  |  | $ 1,900,000 |  |  |  |
Alimera Sciences, Inc | Contingent Value Rights Agreement |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration classified as equity, fair value disclosure |  |  |  |  |  |  | $ 6,000,000 |  |  |
2026 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment, revenue achievement |  | $ 140,000,000.0 |  |  |  |  |  |  |  |
Business combination, milestone payment multiplier |  | 0.25 |  |  |  |  |  |  |  |
Business combination, divisible revenue |  | $ 10,000,000 |  |  |  |  |  |  |  |
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement |  |  |  |  |  |  |  |  |  |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment, revenue achievement |  | $ 160,000,000.0 |  |  |  |  |  |  |  |
Business combination, milestone payment multiplier |  | 0.25 |  |  |  |  |  |  |  |
Business combination, divisible revenue |  | $ 15,000,000 |  |  |  |  |  |  |  |
Contingent consideration, milestone payment, CVRs agreement business days |  | 15 days |  |  |  |  |  |  |  |

X
- Definition Achievement of Milestones Payment Period + References No definition available. + Details
Name: | anip_AchievementOfMilestonesPaymentPeriod
Namespace Prefix: | anip_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Additional Quarterly Payment + References No definition available. + Details
Name: | anip_CollaborativeArrangementAdditionalQuarterlyPayment
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Quarterly Guaranteed Payments + References No definition available. + Details
Name: | anip_CollaborativeArrangementNumberOfQuarterlyGuaranteedPayments
Namespace Prefix: | anip_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Owed Net Profit Generated by Sales, Percentage + References No definition available. + Details
Name: | anip_CollaborativeArrangementOwedNetProfitGeneratedBySalesPercentage
Namespace Prefix: | anip_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Percentage of Net Profit Generated by Sales, Quarterly Payment Due, Accrued + References No definition available. + Details
Name: | anip_CollaborativeArrangementPercentageOfNetProfitGeneratedBySalesQuarterlyPaymentDueAccrued
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Percentage of Net Profit Generated by Sales, Quarterly Payment Due, Maximum + References No definition available. + Details
Name: | anip_CollaborativeArrangementPercentageOfNetProfitGeneratedBySalesQuarterlyPaymentDueMaximum
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Royalty Payable on Revenue, Threshold + References No definition available. + Details
Name: | anip_CollaborativeArrangementRoyaltyPayableOnRevenueThreshold
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Up-front Payment + References No definition available. + Details
Name: | anip_CollaborativeArrangementUpFrontPayment
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Consideration, Milestone Payment, Contingent Value Rights, Distribution Period + References No definition available. + Details
Name: | anip_ContingentConsiderationMilestonePaymentContingentValueRightsAgreementBusinessDays
Namespace Prefix: | anip_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Consideration, Milestone Payment, Denominator + References No definition available. + Details
Name: | anip_ContingentConsiderationMilestonePaymentDenominator
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Consideration, Milestone Payment, Multiplier + References No definition available. + Details
Name: | anip_ContingentConsiderationMilestonePaymentMultiplier
Namespace Prefix: | anip_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contingent Consideration, Milestone Payment, Revenue Achievement + References No definition available. + Details
Name: | anip_ContingentConsiderationMilestonePaymentRevenueAchievement
Namespace Prefix: | anip_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of contingent consideration in a business combination that is classified in shareholders' equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E + Details
Name: | us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 43 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets. + References No definition available. + Details
Name: | us-gaap_InterestRateDerivativeAssetsAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cost of the investment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details
Name: | us-gaap_InvestmentOwnedAtCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=anip_AlimeraSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=anip_CGOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anip_AccruedLicensorPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anip_EyePointAgreementsMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anip_AlimeraSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anip_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | anip_PaymentTypeAxis=anip_A2026MilestoneRevenuePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | anip_PaymentTypeAxis=anip_A2027MilestoneRevenuePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |